DOJ Fraud Division Directive 26-12: What Companies Need to Know About the Latest Corporate Fraud Enforcement Priorities
What You Need To Know
- On October 1, 2026, DOJ’s National Fraud Enforcement Division issued Directive 26-12. It requires the Fraud Division’s prosecutors to report all corporate investigations to the Division’s new Corporate Enforcement Section and to work with that section through the life of each case.
- The directive lists 10 factors that prosecutors must give “great weight” when deciding whether to charge a company and when negotiating pleas or other agreements. Several of them turn on the scope of the conduct, such as duration, geographic reach, number of victims, and dollar loss.
- The Fraud Division’s corporate investigative priorities are health care fraud, government contract and procurement fraud, significant revenue evasion, and tariff, import, and forced-labor offenses.
- The directive also instructs Fraud Division leadership to develop whistleblower incentive programs. Together with the Division’s data analytics efforts, this may shorten the time companies have to identify and self-report misconduct.
On October 1, 2026, Assistant Attorney General Colin M. McDonald, who leads DOJ’s National Fraud Enforcement Division (the Fraud Division), issued Directive 26-12, “Corporate Enforcement in the Fight Against Fraud.” The directive does not change the elements of any federal crime. It also leaves DOJ’s existing corporate enforcement framework in place: it requires prosecutors to follow the existing Principles of Federal Prosecution of Business Organizations.
What the directive changes is process and emphasis. It sends corporate matters through a single, centralized section, and it identifies the considerations that should weigh most heavily when prosecutors decide how to treat a company.
Background: DOJ's National Fraud Enforcement Division
The Fraud Division is new. The White House announced its creation in January 2026, and McDonald was sworn in as its first assistant attorney general on April 1.
On April 7, then-Acting Attorney General Todd Blanche directed the Fraud Division to take operational control of three components that had been part of the DOJ’s Criminal Division: the Tax Section, the Health Care Fraud Unit, and the Market, Government, and Consumer Fraud Unit. McDonald’s August 13 memorandum set out the Division’s priorities and structure, including the Corporate Enforcement Section. A final rule published August 18 formalized the Division’s jurisdiction.
The Division did not assume responsibility for all fraud matters. The Criminal Division’s former Fraud Section, now called the White Collar and Corporate Enforcement Section, continues to handle certain fraud matters. And civil False Claims Act enforcement remains with DOJ’s Civil Division.
What the Directive Does
It centralizes the handling of corporate cases.
- Within seven days of the directive, by October 8, Fraud Division prosecutors must report all ongoing corporate investigations to the Chief of the Corporate Enforcement Section.
- Prosecutors must also promptly notify the section of new corporate investigations and of major developments in existing ones.
- The section will participate “as necessary and appropriate.”
- The directive calls for close coordination “from case intake through completion of any corporate resolution or litigation.”
The directive oversight of corporate resolutions to the Corporate Enforcement Section. The section now has “primary responsibility for evaluating a company’s compliance with the terms of any corporate criminal resolution.” That includes reviewing compliance program commitments and the reporting a company owes under its agreement.
DOJ’s stated goals are consistency across the Fraud Division and freeing other prosecutors to pursue new cases.
The Fraud Division’s Corporate Enforcement Priorities
In opening and conducting corporate investigations, prosecutors are directed to prioritize fraud schemes involving:
- The health care industry, including health care fraud, distribution of controlled substances, and violations of the Federal Food, Drug, and Cosmetic Act (FDCA)
- The public trust or financial integrity of Americans and markets related to procurement, government contracts, and other government functions
- Significant evasion of internal or external revenue
- Tariff evasion, importation of goods or services, or forced labor
The 10 Factors That Will Weigh Heavily in Corporate Charging Decisions
The directive requires prosecutors to “place great weight” on the following factors in deciding whether to bring charges and in negotiating plea or other agreements:
- Knowledge of or involvement in the fraud scheme by corporate management
- Efforts to conceal fraud from government agencies or auditors, or otherwise to impede or obstruct a government function or oversight
- Conduct furthering the scheme that lasts three years or more
- Actions that threaten the safety or security of Americans, including military readiness
- Conduct that causes substantial financial hardship to a taxpayer-funded program or government function
- Conduct that affects multiple taxpayer-funded programs or government functions
- Conduct that affects three or more federal districts
- Conduct that results in financial harm to 25 or more victims or $25 million or more in loss
- Conduct that involves the exfiltration of American dollars to support foreign adversaries
- Conduct that involves immigration offenses
The list is non-exhaustive. Prosecutors may consider other relevant factors consistent with DOJ's Justice Manual.
How to Read the Factors
These factors are not thresholds, and they do not substitute for proof of criminal intent.
Some of them, such as management involvement and concealment, reflect considerations prosecutors have long weighed. Others, such as duration, geographic reach, number of victims, and dollar loss, measure the scope of the conduct. Companies with national operations or large customer bases may meet those size-based factors in the ordinary course of business. Where prosecutors are deciding among declining a case, entering an agreement, or bringing charges, the size-based factors could tip the scales in new ways.
The directive also contains important limiting language. It states that the Fraud Division will “firmly guard against overbroad corporate enforcement—rightly dividing between shades of corporate malfeasance—lest we interfere with legitimate business operations.” It also reminds prosecutors to exercise “thoughtful and pragmatic judgment” in applying these factors. Companies engaging with the Division should keep this language in mind, particularly where a company's reach reflects its business model rather than the design of any scheme.
For Growth-Stage Tech and Life Sciences Companies
Several of the Fraud Division’s priorities intersect with how growth-stage tech and life sciences companies operate.
Digital health, telehealth, diagnostics, and device companies fall within the first priority, which covers fraud schemes involving controlled substances and Federal Food, Drug, and Cosmetic Act (FDCA) violations. The Criminal Division continues to handle certain matters in this area as well, so companies may encounter more than one DOJ component with an interest in the same conduct.
Companies that sell to the federal government, including providers of software, cloud services, AI, and defense and space technology fall within the second priority. Civil False Claims Act cases remain with the Civil Division. Still, the directive’s emphasis on an “all-tools approach” suggests closer coordination between criminal and civil fraud enforcement.
Hardware and other import-dependent companies should note that tariff evasion, import fraud, and forced labor are named priorities. Customs classification, valuation, and country-of-origin practices, along with supply-chain diligence, deserve attention at the legal and compliance level.
Whistleblowers and Data Analytics
The directive states that the Fraud Division’s policies “must encourage and protect the disclosure of information by whistleblowers, including by those who participated in the criminal conduct.” It directs Division leadership to design and implement whistleblower incentive programs. Details have not yet been announced.
The directive also describes the Division’s National Fraud Detection Center as using data analytics to generate leads and open investigations. Taken together, these developments suggest that potential misconduct may increasingly come to DOJ’s attention through insiders or through data, sometimes before a company has identified it. The Corporate Enforcement and Voluntary Self-Disclosure Policy (CEP) continues to provide the greatest benefits to companies that self-disclose before the government learns of the misconduct.
What Boards and Founders Should Consider Now
- Review compliance programs in the priority areas. These include controlled-substance prescribing, FDCA obligations, government contract billing and pricing, customs and import practices, and supply-chain diligence.
- Strengthen internal reporting channels and anti-retaliation policies so employees can raise concerns internally. Companies should not suggest to employees that the company can shield them from individual exposure.
- Engage experienced counsel early when potential issues arise. Early decisions about preservation, internal review, and disclosure can significantly affect outcomes.